PPI-2458
information and resources from the National Cancer Institute
NCI Thesaurus | PPI-2458
A synthetic derivative of fumagillin with antineoplastic and cytotoxic properties. PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class. NCI Thesaurus | PPI-2458
A synthetic derivative of fumagillin with antineoplastic and cytotoxic properties. PPI-2458 irreversibly inhibits the enzyme methionine aminopeptidase type 2 (MetAP2), thereby preventing abnormal cell growth and angiogenesis. PPI-2458 is reported to have a better toxicity profile compared to other agents of its class.
|
|
|
|
news articles
PRAECIS PHARMACEUTICALS INCORPORATED Reports Third Quarter 2005 ... Nov 4, 2005
Genetic Engineering News, ...incurred during the third quarter of 2005 related primarily to clinical development of the Company's investigational compound, PPI-2458, the advancement of its ...
PRAECIS PHARMACEUTICALS INCORPORATED To Present at the Rodman & ... Nov 7, 2005
Genetic Engineering News, PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for non-Hodgkin's lymphoma and solid tumors, as well as an innovative drug discovery ...
|
|
